For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne muscular dystrophy, aging or other degenerative conditions, muscle loss can ...

The global Duchenne muscular dystrophy (DMD) market is valued approximately at USD 1.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.7% over the forecast period ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne ...

Rachel Kondo, creator and head writer of the hit series Shogun, has never shied away from confronting life’s most difficult ...

The Family Achievement Center will offer family-oriented physical, occupational and speech therapies once it opens in May.

Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...

Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration ...

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...